Trial: 202003106

EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)

Phase

II

Principal Investigator

Bagegni, Nusayba

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov